Resistance to HCV nucleoside analogue inhibitors of hepatitis C virus RNA-dependent RNA polymerase

Current Opinion in Virology

Volumn 3, Issue 5, 2013, Pages 508-513

  Najera, Isabel ^a  

^a Infectious Diseases Discovery   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 072; ABT 267; ABT 333; ABT 450; ALS 2200; ANTIVIRUS AGENT; ASUNAPREVIR; BI 207127; BMS 791325; BMS 986094; DACLASTAVIR; DANOPREVIR; FALDAPREVIR; GS 9256; IDX 184; IDX 719; LEDIPASVIR; LOMIBUVIR; MERICITABINE; MK 5172; MK 8742; NARLAPREVIR; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; PROTEINASE INHIBITOR; RNA DIRECTED RNA POLYMERASE INHIBITOR; SETROBUVIR; SIMEPREVIR; SOFOSBUVIR; SOVAPREVIR; TEGOBUVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANIPREVIR; VEDROPREVIR;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG POTENCY; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MUTANT; PERSISTENT VIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; RNA VIRUS; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN; WILD TYPE;

ANIMALS; HEPACIVIRUS; HEPATITIS C; HUMANS; NUCLEOSIDES; PROTEASE INHIBITORS; RNA REPLICASE; VIRAL PROTEINS;

EID: 84885947903     PISSN: 18796257     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coviro.2013.08.011     Document Type: Review

References (49)

1. K. Mohd Hanafiah, J. Groeger, A.D. Flaxman, and S.T. Wiersma Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence Hepatology 57 2013 1333 1342 10.1002/hep.26141 Feb 4 [Epub 2013]
2. FDA Approves Merck's VICTRELIS ((boceprevir), First-in-Class Oral Hepatitis C Virus (HCV) Protease Inhibitor 2011 Press release issued by Merck 13 May. Available at http://www.merck.com/newsroom/news-release-archive/ prescription-medicine-news/2011-0513.html (accessed 14.06.11)
3. FDA Approves INCIVEK((telaprevir) for People with Hepatitis C 2011 Press release issued by Vertex 23 May. Available at http://investors.vrtx.com/ releasedetail.cfm?ReleaseID=580154 (accessed 14.06.11)
4. J.G. McHutchison, G.T. Everson, and S.C. Gordon Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection N Engl J Med 360 2009 1827 1838
5. J.G. McHutchison, M.P. Manns, and A.J. Muir Telaprevir for previously treated chronic HCV infection N Engl J Med 362 2010 1292 1303
6. B.R. Bacon, S.C. Gordon, and E. Lawitz Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
7. F. Poordad, J. McCone Jr., and B.R. Bacon Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
8. I.M. Jacobson, J.G. McHutchison, and G. Dusheiko Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
9. S. Zeuzem, P. Andreone, and S. Pol Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
10. E. Domingo, J. Sheldon, and C. Perales Viral quasispecies evolution Microbiol Mol Biol Rev 76 2012 159 216
11. L. Rong, H. Dahari, R.M. Ribeiro, and A.S. Perelson Rapid emergence of protease inhibitor resistance in hepatitis C virus Sci Transl Med 2 2010 30 32
12. S. Le Pogam, A. Seshaadri, A. Kosaka, S. Chiu, H. Kang, S. Hu, S. Rajyaguru, J. Symons, N. Cammack, and I. Nájera Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients J Antimicrob Chemother 61 2008 1205 1216 (Pubitemid 351753583)
13. T. Kuntzen, J. Timm, and A. Berical Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients Hepatology 48 2008 1769 1778
14. S. Le Pogam, J.M. Yan, M. Chhabra, M. Ilnicka, H. Kang, A. Kosaka, S. Ali, D.J. Chin, N.S. Shulman, and P. Smith Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short-term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir Antimicrob Agents Chemother 56 2012 5494 5502
15. A. Trevino, C. de Mendoza, and P. Parra Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV-coinfected patients Antivir Ther 16 2011 413 416
16. R. Alves, A.T. Queiroz, M.G. Pessoa, E.F. da Silva, D.F. Mazo, F.J. Carrilho, R.J. Carvalho-Filho, and I.M. de Carvalho The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank J Viral Hepat 20 2013 414 421
17. N.P. Lam, A.U. Neumann, D.R. Gretch, T.E. Wiley, A.S. Perelson, and T.J. Layden Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa Hepatology 26 1997 226 231 (Pubitemid 27280329)
18. P. Simmonds The origin of hepatitis C virus Curr Top Microbiol Immunol 369 2013 1 15
19. M.F. McCown, S. Rajyaguru, S. Le Pogam, S. Ali, W.R. Jiang, H. Kang, J. Symons, N. Cammack, and I. Najera The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors Antimicrob Agents Chemother 52 2008 1604 1612 (Pubitemid 351614649)
20. J.M. Gottwein, T.K. Scheel, T.B. Jensen, L. Ghanem, and Bukh Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses J. Gastroenterol 141 2011 1067 1079
21. T.K. Scheel, J.M. Gottwein, L.S. Mikkelsen, T.B. Jensen, and J. Bukh Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α Gastroenterology 140 2011 1032 1042
22. S. De Meyer, A. Ghys, G.R. Foster, M. Beumont, B. Van Baelen, T.I. Lin, I. Dierynck, H. Ceulemans, and G. Picchio Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes J Viral Hepat 20 2013 395 403
23. D. Hernandez, N. Zhou, J. Ueland, A. Monikowski, and F. McPhee Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors J Clin Virol 57 2013 13 18
24. M.H. Powdrill, E.P. Tchesnokov, R.A. Kozak, R.S. Russell, R. Martin, E.S. Svarovskaia, H. Mo, R.D. Kouyos, and M. Götte Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance Proc Natl Acad Sci U S A 108 2011 20509 20513
25. M.F. McCown, S. Rajyaguru, S. Kular, N. Cammack, and I. Najera GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796 Antimicrob Agents Chemother 53 2009 2129 2132
26. P. Halfon, and S. Locarnini Hepatitis C virus resistance to protease inhibitors J Hepatol 55 2011 192 206
27. D. Leen, V. Inge, F. Mathy, and N. Johan Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis C virus replication Antimicrob Agents Chemother 55 2011 4103 4113
28. C. Sarrazin, T.L. Kieffer, and D. Bartels Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir Gastroenterology 132 2007 1767 1777 (Pubitemid 46677938)
29. H.W. Reesink, S. Zeuzem, and C.J. Weegink Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study Gastroenterology 131 2006 997 1002 (Pubitemid 44498690)
30. Incivek Prescribing Information 2011 Vertex Pharmaceuticals, Inc. Cambridge, MA, USA
31. Victrelis Prescribing Information 2011 Schering Corporation, a subsidiary of Merck and Co. Whitehouse Station, NJ, USA
32. C.A. Lesburg, M.B. Cable, E. Ferrari, Z. Hong, A.F. Mannarino, and P.C. Weber Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site Nat Struct Biol 6 1999 937 943 (Pubitemid 29463307)
33. S. Le Pogam, H. Kang, S.F. Harris, V. Leveque, A.M. Giannetti, S. Ali, W.R. Jiang, S. Rajyaguru, G. Tavares, and C. Oshiro Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus J Virol 80 2006 6146 6154 (Pubitemid 43849192)
34. M.J. Sofia, D. Bao, W. Chang, J. Du, D. Nagarathnam, S. Rachakonda, P.G. Reddy, B.S. Ross, P. Wang, and H.R. Zhang Discovery of a β-d-2′- deoxy-2′-α-fluoro-2′-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus J Med Chem 53 2010 7202 7218
35. E. Lawitz, A. Mangia, D. Wyles, M. Rodriguez-Torres, T. Hassanein, S.C. Gordon, M. Schultz, M.N. Davis, Z. Kayali, and K.R. Reddy Sofosbuvir for previously untreated chronic hepatitis C infection N Engl J Med 368 2013 1878 1887
36. L.J. Stuyver, T.R. McBrayer, P.M. Tharnish, J. Clark, L. Hollecker, S. Lostia, T. Nachman, J. Grier, M.A. Bennett, and M.Y. Xie Inhibition of hepatitis C replicon RNA synthesis by beta-d-2′-deoxy-2′-fluoro-2′-C- methylcytidine: a specific inhibitor of hepatitis C virus replication Antivir Chem Chemother 17 2006 79 87
37. H. Ma, W.R. Jiang, and N. Robledo Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-d-2′-deoxy- 2′-fluoro-2′-C-methylcytidine (PSI-6130) and identification of a novel active 5′-triphosphate species J Biol Chem 282 2007 29812 29820 (Pubitemid 350035263)
38. P.J. Pockros, D. Jensen, N. Tsai, R. Taylor, A. Ramji, C. Cooper, R. Dickson, A. Tice, R. Kulkarni, and J.M. Vierling A randomized trial of mericitabine plus peginterferon alfa-2a/ribavirin for 24 weeks in treatment-naive HCV genotype 1/4 patients Hepatology 2013 [Epub ahead of print]
39. C.H. Tan, J. Deval, H. Kang, C. Moy, Z. Jin, A. Jekle, R. Rijnbrand, T. Kieffer, L.M. Blatt, and S.M. Chanda ALS-2200 (VX-135) Viral Kinetic Study Shows Significant Reduction in HCV RNA in People with Genotype 1 Hepatitis C Virus Infection and Cirrhosis, and in People with Genotypes 2, 3 or 4 HCV Infection 2013 Alios BioPharma Incorporated/Vertex Pharmaceuticals Incorporated South San Francisco, CA, USA/Cambridge, MA, USA
40. J.H. Vernachio, B. Bleiman, K.D. Bryant, S. Chamberlain, D. Hunley, J. Hutchins, B. Ames, E. Gorovits, B. Ganguly, and A. Hall INX-08189, a phosphoramidate prodrug of 6-O-methyl-2′-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties Antimicrob Agents Chemother 55 2011 1843 1851
41. A.M. Lam, C. Espiritu, S. Bansal, H.M. Micolochick Steuer, V. Zennou, M.J. Otto, and P.A. Furman Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA J Virol 85 2011 12334 12342
42. S. Le Pogam, W.R. Jiang, and V. Leveque In vitro selected Con1 subgenomic replicons resistant to 2′-C-methyl-cytidine or to R1479 show lack of cross resistance Virology 351 2006 349 359 (Pubitemid 44108072)
43. A.M. Lam, C. Espiritu, S. Bansal, H.M. Micolochick Steuer, C. Niu, V. Zennou, M. Keilman, Y. Zhu, S. Lan, M.J. Otto, and P.A. Furman Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus Antimicrob Agents Chemother 56 2012 3359 3368
44. S. Ali, V. Leveque, and S. Le Pogam Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479 Antimicrob Agents Chemother 52 2008 4356 4369
45. G. Migliaccio, J.E. Tomassini, and S.S. Carroll Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro J Biol Chem 278 2003 49164 49170
46. H. Wedemeyer, D. Jensen, R. Herring Jr., P. Ferenci, M.M. Ma, S. Zeuzem, M. Rodriguez-Torres, N. Bzowej, P. Pockros, and J. Vierling A randomized trial of mericitabine plus peginterferon alfa-2a/ribavirin therapy in treatment-naive HCV Genotype 1/4 patients Hepatology 2013 10.1002/hep.26274 Jan 24 [Epub ahead of print]
47. S. Le Pogam, A. Seshaadri, A. Ewing, H. Kang, A. Kosaka, J.M. Yan, M. Berrey, B. Symonds, A. De La Rosa, N. Cammack, and I. Nájera RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) replication and selection of resistant variants in HCV-infected patients J Infect Dis 202 2010 1510 1519
48. I.M. Jacobson, S.C. Gordon, K.V. Kowdley, E.M. Yoshida, M. Rodriguez-Torres, M.S. Sulkowski, M.L. Shiffman, E. Lawitz, G. Everson, and M. Bennett Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options N Engl J Med 368 2013 1867 1877
49. A.D. Kwong, I. Najera, J. Bechtel, S. Bowden, J. Fitzgibbon, P. Harrington, D. Kempf, T.L. Kieffer, D. Koletzki, and G. Kukolj Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG Gastroenterology 140 2011 755 760